Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
2020
CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical efficacy and safety in patients with Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis and chronic plaque psoriasis.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
7
Citations
NaN
KQI